Aligning interests

Nature Biotechnology 26, 1199 (2008). doi:10.1038/nbt1108-1199

As sources of funding dwindle, could the health insurance sector do more to support biotech innovation and help itself at the same time?

Gunvalson decision sends shockwaves through industry

Nature Biotechnology 26, 1201 (2008). doi:10.1038/nbt1108-1201

Author: Malorye Allison

India partners to fast track biotech

Nature Biotechnology 26, 1202 (2008). doi:10.1038/nbt1108-1202

Author: Killugudi Jayaraman

FDA cracks down on labeling, initiates trial result reporting

Nature Biotechnology 26, 1203 (2008). doi:10.1038/nbt1108-1203

Authors: Randy Osborne & Emily Waltz

Polar biotech

Nature Biotechnology 26, 1204 (2008). doi:10.1038/nbt1108-1204a

Author: Hannah Hoag

Deaths stalk GLP-1 agonist

Nature Biotechnology 26, 1204 (2008). doi:10.1038/nbt1108-1204b

Author: Jodi Hyer

FDA transgenic animal guidance finally surfaces

Nature Biotechnology 26, 1205 (2008). doi:10.1038/nbt1108-1205

Author: Jeffrey L Fox

Amgen's bone blockbuster

Nature Biotechnology 26, 1206 (2008). doi:10.1038/nbt1108-1206a

Author: Hayley Birch

Enbrel patent feud

Nature Biotechnology 26, 1206 (2008). doi:10.1038/nbt1108-1206b

Author: Asher Mullard